Diseases, Conditions, Syndromes

US to put up $2.1 bn for Sanofi, GSK coronavirus vaccine

Pharma giants Sanofi and GSK will receive up to $2.1 billion from the US government for the development of a COVID-19 vaccine, the companies said Friday, as the world continues to be ravaged by the coronavirus epidemic.

Pediatrics

Nirsevimab injection cuts RSV-linked infections in preemies

(HealthDay)—Nirsevimab prevents respiratory syncytial virus (RSV)-associated lower respiratory tract infections in healthy preterm infants, while maternal RSV fusion (F) protein nanoparticle vaccination did not meet the ...

Diseases, Conditions, Syndromes

Sanofi expands US vaccine venture in COVID-19 race

French pharmaceutical giant Sanofi said Tuesday that it would invest $425 million to expand its vaccine development venture with US start-up Translate Bio as they aim to find a COVID-19 vaccine by next year.

Other

Coronavirus boosts sales for French pharma giant Sanofi

French pharmaceutical giant Sanofi said Friday that its first quarter sales surged in part due to stockpiling of the painkiller Doliprane, as other companies around the world struggle during the coronavirus pandemic.

Medications

Sanofi says charged in birth defects case

Pharmaceutical firm Sanofi has been charged in France with failure to adequately warn patients and causing injury over an anti-epilepsy drug linked to birth defects following a three-year probe.

Oncology & Cancer

In first for EU, anti-skin cancer drug approved

French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU.

page 4 from 13